Zobrazeno 1 - 10
of 418
pro vyhledávání: '"L. Vanneste"'
Autor:
Tony Reglinski, Kirstin V. Wurms, Joel L. Vanneste, Annette Ah Chee, Magan Schipper, Deirdre Cornish, Janet Yu, Jordan McAlinden, Duncan Hedderley
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 21, p 15952 (2023)
Pathogen susceptibility and defence gene inducibility were compared between the Actinidia arguta cultivar ‘Hortgem Tahi’ and the two cultivars of A. chinensis ‘Hayward’ and ‘Zesy002′. Plants were treated with acibenzolar-s-methyl (ASM) or
Externí odkaz:
https://doaj.org/article/270f8227a1e24bfaba7560860de8b4d0
Effector loss drives adaptation of Pseudomonas syringae pv. actinidiae biovar 3 to Actinidia arguta.
Autor:
Lauren M Hemara, Jay Jayaraman, Paul W Sutherland, Mirco Montefiori, Saadiah Arshed, Abhishek Chatterjee, Ronan Chen, Mark T Andersen, Carl H Mesarich, Otto van der Linden, Minsoo Yoon, Magan M Schipper, Joel L Vanneste, Cyril Brendolise, Matthew D Templeton
Publikováno v:
PLoS Pathogens, Vol 18, Iss 5, p e1010542 (2022)
A pandemic isolate of Pseudomonas syringae pv. actinidiae biovar 3 (Psa3) has devastated kiwifruit orchards growing cultivars of Actinidia chinensis. In contrast, A. arguta (kiwiberry) is not a host of Psa3. Resistance is mediated via effector-trigge
Externí odkaz:
https://doaj.org/article/e5274cb63902498ca5d3f1034ca88ec4
Autor:
Tony Reglinski, Joel L. Vanneste, Magan M. Schipper, Deirdre A. Cornish, Janet Yu, Jenny M. Oldham, Christina Fehlmann, Frank Parry, Duncan Hedderley
Publikováno v:
Plants, Vol 12, Iss 4, p 833 (2023)
The plant defence inducer Actigard® (acibenzolar-S-methyl [ASM]) is applied before flowering and after fruit harvest to control bacterial canker in kiwifruit caused by Pseudomonas syringae pv. actinidiae. Pre-flowering application of ASM is known to
Externí odkaz:
https://doaj.org/article/550cb1be6f7642d18390ccb358bc58a1
Autor:
Anshu Ankolekar, Ben G. L. Vanneste, Esther Bloemen-van Gurp, Joep G. van Roermund, Evert J. van Limbergen, Kees van de Beek, Tom Marcelissen, Victor Zambon, Matthias Oelke, Andre Dekker, Cheryl Roumen, Philippe Lambin, Adriana Berlanga, Rianne Fijten
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Patient decision aids (PDAs) can support the treatment decision making process and empower patients to take a proactive role in their treatment pathway while using a shared decision-making (SDM) approach making participatory medic
Externí odkaz:
https://doaj.org/article/8ba4766ec8e54e03a9ec4ea0f38e3d39
Autor:
Vania Michelotti, Antonella Lamontanara, Giampaolo Buriani, Luigi Orrù, Antonio Cellini, Irene Donati, Joel L. Vanneste, Luigi Cattivelli, Gianni Tacconi, Francesco Spinelli
Publikováno v:
BMC Genomics, Vol 19, Iss 1, Pp 1-22 (2018)
Abstract Background Since 2007, bacterial canker caused by Pseudomonas syringae pv. actinidiae (Psa) has become a pandemic disease leading to important economic losses in every country where kiwifruit is widely cultivated. Options for controlling thi
Externí odkaz:
https://doaj.org/article/da4652896f6949e991ba8bf99196b586
Autor:
Zhengfei Zhu, Jianjiao Ni, Xuwei Cai, Shengfa Su, Hongqing Zhuang, Zhenzhou Yang, Ming Chen, Shenglin Ma, Conghua Xie, Yaping Xu, Jiancheng Li, Hong Ge, Anwen Liu, Lujun Zhao, Chuangzhou Rao, Congying Xie, Nan Bi, Zhouguang Hui, Guangying Zhu, Zhiyong Yuan, Jun Wang, Lina Zhao, Wei Zhou, Chai Hong Rim, Arturo Navarro-Martin, Ben G. L. Vanneste, Dirk De Ruysscher, J. Isabelle Choi, Jacek Jassem, Joe Y. Chang, Lucyna Kepka, Lukas Käsmann, Michael T. Milano, Paul Van Houtte, Rafal Suwinski, Alberto Traverso, Hiroshi Doi, Yang-Gun Suh, Georges Noël, Natsuo Tomita, Roman O. Kowalchuk, Terence T. Sio, Baosheng Li, Bing Lu, Xiaolong Fu
Publikováno v:
Translational Lung Cancer Research, 11, 1763-1795. AME Publishing Company
Background: Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for most cases. While radiotherapy has historically served as a palliative modality in metastatic NSCLC, considerable a
Autor:
Yvonka van Wijk, Bram Ramaekers, Ben G. L. Vanneste, Iva Halilaj, Cary Oberije, Avishek Chatterjee, Tom Marcelissen, Arthur Jochems, Henry C. Woodruff, Philippe Lambin
Publikováno v:
Cancers, Vol 13, Iss 11, p 2687 (2021)
The aim of this study is to build a decision support system (DSS) to select radical prostatectomy (RP) or external beam radiotherapy (EBRT) for low- to intermediate-risk prostate cancer patients. We used an individual state-transition model based on
Externí odkaz:
https://doaj.org/article/1c49080d493d4fe086fa499caafac49e
Publikováno v:
Transl Lung Cancer Res
Several studies have established that radiotherapy (RT) in combination with immunotherapy (IO) has a strong synergistic effect. RT changes the tumor microenvironment, generates local inflammation reactions, and enhances immunostimulatory effects, whi
Autor:
Ludy C.H.W. Lutgens, Ben G. L. Vanneste, K. Reynders, Evert J. Van Limbergen, Jarno Melenhorst, Joep G. H. van Roermund, Tom Marcelissen
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 27, Iss, Pp 121-125 (2021)
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, 27, 121-125. Elsevier Ireland Ltd
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, 27, 121-125. Elsevier Ireland Ltd
Highlights • Radiotherapy in patients with inflammatory bowel disease remains controversial. • A biodegradable balloon is inserted between the prostate and the rectal wall. • The balloon pushes the anterior rectal wall outside of the high-dose
Autor:
Eline H. Huele, Maureen J.B. Aarts, Jacqueline M. Tromp, Michael Schaapveld, Ronald de Wit, Hetty A van den Berg, J. Alfred Witjes, Jourik A. Gietema, Tineke J. Smilde, Harmke J. Groot, Ben G. L. Vanneste, Gerard Groenewegen, J.L.H. Ruud Bosch, Janine Nuver, Simon Horenblas, Richard P. Meijer, Peter De Brouwer, Joost M. Blok
Publikováno v:
Journal of Clinical Oncology, 39, 4, pp. 319-327
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(4), 319-327. American Society of Clinical Oncology
Journal of clinical oncology, 39(4), 319-327. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(4):JCO2002352, 319-330. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 39(4), 319-+. American Society of Clinical Oncology
Journal of Clinical Oncology, 39, 319-327
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(4), 319-327. American Society of Clinical Oncology
Journal of clinical oncology, 39(4), 319-327. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(4):JCO2002352, 319-330. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 39(4), 319-+. American Society of Clinical Oncology
Journal of Clinical Oncology, 39, 319-327
PURPOSE Patients with testicular germ cell tumor (TGCT) are at increased risk of developing a contralateral TGCT (CTGCT). Although some studies suggest that prior treatment with platinum-based chemotherapy affects CTGCT risk, a relationship between C